Systemic Lupus Erythematosus – Current Treatment – Current Treatment: Physician Insights – Systemic Lupus Erythematosus (EU5)

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the main treatments for SLE. Unfortunately, until 2020, Benlysta (GlaxoSmithKline) was the only approved targeted therapy for SLE. Over the past four years, SLE treatment landscape has witnessed the approval of two novel therapies (i.e., AstraZeneca’s Saphnelo and Aurinia’s Lupkynis) and the launch of subcutaneous form of Benlysta, which further expands physicians’ treatment armamentarium. Indeed, the availability of these agents has influenced physicians’ prescribing behavior and will continue to impact the treatment landscape.Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the main treatments for SLE. Unfortunately, until 2020, Benlysta (GlaxoSmithKline) was the only approved targeted therapy for SLE. Over the past four years, SLE treatment landscape has witnessed the approval of two novel therapies (i.e., AstraZeneca’s Saphnelo and Aurinia’s Lupkynis) and the launch of subcutaneous form of Benlysta, which further expands physicians’ treatment armamentarium. Indeed, the availability of these agents has influenced physicians’ prescribing behavior and will continue to impact the treatment landscape.

Questions answered:

• What drug classes are the patient share leaders across different lines of therapy? How are different biological agents be positioned in surveyed physicians’ treatment algorithm?
• What are the most influential drivers for treatment selection and under which scenarios do/will physicians prescribe Lupkynis and Saphnelo?
• What are the common treatment scenarios before initiating the different targeted therapy agents (i.e., Benlysta, MabThera, Saphnelo, Lupkynis)? What is the course of action upon discontinuing these agents?
• What factors drive therapy discontinuation and switch? What factors have/will drive recent/anticipated prescribing changes?

Markets covered: France, Germany, Italy, Spain, and the United Kingdom

Primary research: 250 gastroenterologists completed the survey. Of these physicians, 50 were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom. The survey was fielded in April 2025.

Key drugs: Benlysta, MabThera, Saphnelo, Orencia, Lupkynis, mycophenolate mofetil, hydroxychloroquin

Product description

.